PV Bulletin

Extension of e-labelling to P and GSL medicines

The Health Sciences Authority's Therapeutic Products Branch announced an extension of electronic labelling to Pharmacy-only (P) and General Sale List (GSL) medicines, effective 30 June 2026.

Primary source: Health Sciences Authority (HSA) Singapore

PV Impact Brief

Urgency: HighConfidence: high

What changed

The extension of the e-labelling scheme to include Pharmacy-only (P) and General Sale List (GSL) medicines effective from 30 June 2026.

Why it matters

This initiative enhances digital access to product information and safety updates, thus improving the labeling workflows and requiring updates to registration and packaging processes for Marketing Authorization Holders (MAHs).

Action needed

Manufacturers must adjust labeling workflows to incorporate e-labelling mechanisms, such as QR codes, for P and GSL medicines by the stipulated date.

Relevant for
Regulatory Intelligence LeadLabeling LeadQPPV
Processes impacted
Labeling
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Regulatory Update / Notice
Policy status
new
Publication date
2026-06-30
Policy change
The Health Sciences Authority's Therapeutic Products Branch (TPB) announced an extension of electronic labelling (e-labelling) to Pharmacy-only (P) and General Sale List (GSL) medicines, effective 30 June 2026. This initiative follows the previous implementation for Prescription-only Medicines (POM) and aims to enhance digital access to product information.

Key changes

Extension of the e-labelling scheme to include P and GSL categories of therapeutic products. Manufacturers and registration holders can now provide product information through digital means (e.g., QR codes) instead of or in addition to physical leaflets for these categories.

Affected workflows

Labeling

Responsible groups

Regulatory AffairsLabeling OperationsPharmacovigilance

PV impact

Improved accessibility to the latest product information and safety updates for healthcare professionals and consumers. This affects labeling workflows and requires updates to registration and packaging processes for MAHs.

View regulator source

Source document details

Extracted documents

Unable to extract linked source document: https://www.googletagmanager.com/ns.html

Evidence and confidence

Confidence: highSource updated: Jun 30, 2026

Full briefing

Practical implication

Manufacturers must adjust labeling workflows to incorporate e-labelling mechanisms, such as QR codes, for P and GSL medicines by the stipulated date.

This regulatory update mandates that manufacturers and registration holders can provide product information through digital means, such as QR codes, for Pharmacy-only and General Sale List medicines, leading to improved accessibility for healthcare professionals and consumers.

What changed: The extension of the e-labelling scheme to include Pharmacy-only (P) and General Sale List (GSL) medicines effective from 30 June 2026.

Why it matters: This initiative enhances digital access to product information and safety updates, thus improving the labeling workflows and requiring updates to registration and packaging processes for Marketing Authorization Holders (MAHs).

Practical implication: Manufacturers must adjust labeling workflows to incorporate e-labelling mechanisms, such as QR codes, for P and GSL medicines by the stipulated date.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Safety Signals#Regulatory Update / Notice#new#Health Sciences Authority (HSA) Singapore#labeling#policy-change#firecrawl-policy-agent

Related updates for your role

publicTherapeutics Goods Administration · Australia · Updated Jul 20, 2026

Updates on ISO 14155 and N=1 Therapeutics Discussed by TGA

Urgency: High

Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

Inspection ReadinessICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicMedicines and Healthcare products Regulatory Agency (MHRA) · United Kingdom · Updated May 23, 2026

MHRA confirms UK clinical trial safety reporting guidance is effective

Urgency: High

Safety lead to: (1) perform a UK-clinical-trial safety reporting gap assessment against MHRA’s effective guidance sections (MedDRA coding; AE/SAE; RSI governance; SUSARs; annual safety reporting; USMs; serious breaches; temporary suspension), (2) update controlled SOPs/WIs and training records to reflect “effective” status as of 28 Apr 2026, and (3) document deviations/gaps and open CAPA where needed for ongoing UK trials and new submissions.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact4 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Guidance
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Jul 20, 2026

CHMP Draft Agenda for Public Consultation on Thalassaemia and Sickle Cell Disease Guidelines

Urgency: High

Sponsors and MAHs must review and align safety data collection and reporting protocols with the newly adopted guidelines while preparing for implementation of PRAC recommendations stemming from this meeting.

Signal ManagementICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Agenda
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Urgency: High

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Checklist
Read impact briefarrow_forward